Table 4 Head-to-head comparison of the performance and discriminative ability of the seven models in predicting survival for intermediate-stage HCC patients who underwent TACE

ALBI-TAE score

A (Low risk)

44

40.80 (29.04,105.19)

1

ref

B

216

20.14 (17.61,23.85)

2.08 (1.40–3.09)

 < 0.001

C

164

10.58 (9.17,14.13)

3.46 (2.30–5.21)

 < 0.001

D (Very high risk)

56

7.54 (4.37,9.33)

5.10 (3.22–8.09)

 < 0.001

Bolondi’s subclassification for BCLC-B

B1 (Low risk)

126

21.83 (17.28,27.1)

1

ref

B2

243

17.31 (15.34,20.4)

1.21 (0.96–1.53)

0.102

B3

55

9.43 (7.65,12.7)

2.03 (1.45–2.84)

 < 0.001

B4 (High risk)

56

11.61 (9.07,15.9)

1.66 (1.19–2.32)

0.003

HAP score

A (Low risk)

62

33.28 (29.01,44.58)

1

ref

B

200

18.97 (16.92,23.26)

1.86 (1.34–2.58)

 < 0.001

C

162

11.66 (8.94,13.83)

2.88 (2.06–4.03)

 < 0.001

D (High risk)

56

8.23 (7.42,9.46)

3.98 (2.67–5.94)

 < 0.001

mHAP-II score

A (Low risk)

16

49.64 (30.62,NA)

1

ref

B

107

27.33 (23.26,33.3)

2.00 (1.04–3.86)

0.039

C

181

16.85 (15.70,19.5)

3.15 (1.66–5.98)

 < 0.001

D (High risk)

176

9.18 (7.75,11.8)

4.80 (2.52–9.12)

 < 0.001

Tumor burden score

A (Low risk)

24

16.92 (9.17,56.9)

1

ref

B

378

17.81 (16.26,20.7)

1.19 (0.75–1.86)

0.461

C (High risk)

78

8.15 (6.18,13.0)

1.87 (1.14–3.07)

0.014

Six-and-twelve score

A (Low risk)

77

22.1 (15.77,29.0)

1

ref

B

251

19.5 (17.12,23.8)

1.15 (0.87–1.51)

0.335

C (High risk)

152

9.4 (8.34,13.0)

1.75 (1.30–2.35)

 < 0.001

Seven-eleven criteria

A (Low risk)

153

21.6 (17.12,25.8)

1

ref

B

157

18.3 (15.83,24.0)

1.13 (0.89–1.44)

0.312

C (High risk)

170

10.4 (8.94,13.7)

1.65 (1.31–2.08)

 < 0.001

Total

480

16.6 (14.9,18.4)